- The study, led by Dr. Lopa Mishra and published in Cell Reports, provides new mechanistic evidence for role of BF-114 target β2-spectrin in obesity, MASLD, MASH, and HCC
- The findings suggest that targeting β2-spectrin with BF-114 can prevent the progression of liver diseases
- New data builds on earlier studies and further supports BF-114's potential to address major unmet needs in treating obesity-related liver diseases
- Dr. Lopa Mishra, a globally recognized expert in liver disease, has joined BullFrog AI's Scientific Advisory Board to provide strategic insights for advancing BF-114
GAITHERSBURG, Md., Oct. 09, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the publication of new research in the peer-reviewed journal
Cell Reports supporting the potential of BullFrog AI's drug candidate, BF-114 (
SPTBN1 siRNA), in treating a range of liver diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), and hepatocellular carcinoma (HCC). The research was generated in a study led by Lopa Mishra, MD, professor of medicine, Merinoff Endowed Chair and co-director of the Institute for Bioelectronic Medicine at Feinstein Institutes for Medical Research at Northwell Health, Cold Spring Harbor Laboratory.
